NYSE:MED - Medifast Stock Price, News, & Analysis

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Medifast announced a quarterly dividend on Wednesday, December 12th. Stockholders of record on Friday, December 21st will be given a dividend of $0.75 per share on Thursday, February 7th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 2.45%. The ex-dividend date is Thursday, December 20th. This is a positive change from Medifast's previous quarterly dividend of $0.48. View Medifast's Dividend History.

Medifast Inc (NYSE:MED) issued its earnings results on Tuesday, November, 6th. The specialty retailer reported $1.14 EPS for the quarter, hitting the consensus estimate of $1.14. The specialty retailer had revenue of $139.20 million for the quarter, compared to analysts' expectations of $125.20 million. Medifast had a net margin of 10.95% and a return on equity of 43.45%. The company's quarterly revenue was up 80.3% compared to the same quarter last year. During the same period last year, the firm posted $0.55 EPS. View Medifast's Earnings History.

Medifast is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Medifast.

Medifast issued an update on its FY18 earnings guidance on Monday, January, 14th. The company provided earnings per share (EPS) guidance of $4.45-4.50 for the period, compared to the Thomson Reuters consensus estimate of $4.50. The company issued revenue guidance of $492.5-497.5 million, compared to the consensus revenue estimate of $497.04 million.

2 analysts have issued 12 month price targets for Medifast's shares. Their forecasts range from $249.00 to $249.00. On average, they anticipate Medifast's stock price to reach $249.00 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price. View Analyst Price Targets for Medifast.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medifast.

Media coverage about MED stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Medifast earned a daily sentiment score of 0.9 on InfoTrie's scale. They also gave media headlines about the specialty retailer a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an effect on the stock's share price in the next several days.

Some companies that are related to Medifast include MCCORMICK & CO /SH (MKC), WANT WANT CHINA/ADR (WWNTY), Greencore Group (GNCGY), Farmer Bros (FARM), China Marine Food Group (CMFO) and Jammin Java (JAMN).

Medifast's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Chickasaw Capital Management LLC (0.28%), Navellier & Associates Inc (0.22%), Virtu Financial LLC (0.05%), Louisiana State Employees Retirement System (0.04%), State of Alaska Department of Revenue (0.03%) and Matisse Capital (0.02%). Company insiders that own Medifast stock include Charles P Connolly, Constance J Hallquist, Daniel R Chard, Glenn W Welling, Jeremy John Martin, Michael A Hoer, Michael C Macdonald, Ralph Rushton and Simon TP Ridgway. View Institutional Ownership Trends for Medifast.

MED stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Chickasaw Capital Management LLC, Louisiana State Employees Retirement System and First Citizens Bank & Trust Co.. Company insiders that have sold Medifast company stock in the last year include Charles P Connolly, Constance J Hallquist and Michael C Macdonald. View Insider Buying and Selling for Medifast.

MED stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Navellier & Associates Inc, Matisse Capital and State of Alaska Department of Revenue. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Glenn W Welling, Michael A Hoer and Simon TP Ridgway. View Insider Buying and Selling for Medifast.

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MED stock can currently be purchased for approximately $122.21.

Medifast has a market capitalization of $1.44 billion and generates $301.56 million in revenue each year. The specialty retailer earns $27.72 million in net income (profit) each year or $2.29 on an earnings per share basis. Medifast employs 399 workers across the globe.

The official website for Medifast is http://www.medifast1.com.

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]